Benzinga | Aug 3, 2021 06:34AM EDT

Sage Therapeutics Q2 EPS $(1.83) Misses $(1.69) Estimate, Sales $1.64M Miss $2.01M Estimate

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.83) per share which missed the analyst consensus estimate of $(1.69) by 8.28 percent. This is a 12.02 percent increase over losses of $(2.08) per share from the same period last year. The company reported quarterly sales of $1.64 million which missed the analyst consensus estimate of $2.01 million by 18.26 percent. This is a 50.87 percent increase over sales of $1.09 million the same period last year.